Suppr超能文献

日本慢性肾脏病 G5 期的患病率和发病率。

Prevalence and incidence of chronic kidney disease stage G5 in Japan.

机构信息

Department of Nephrology, Faculty of Medicine, University of Tsukuba, 1-1-1, Ten-oudai, Tsukuba, Ibaraki, 305-8575, Japan,

出版信息

Clin Exp Nephrol. 2015 Feb;19(1):54-64. doi: 10.1007/s10157-014-0978-x. Epub 2014 May 13.

Abstract

The prevalence and incidence of end-stage kidney disease (ESKD) have continued to increase worldwide. Japan was known as having the highest prevalence of ESKD in the world; however, Taiwan took this place in 2001, with the USA still in third position. However, the prevalence data from Japan and Taiwan consisted of dialysis patients only. The prevalence and incidence of Kidney Transplantation (KT) in Japan were quite low, and the number of KT patients among those with ESKD was regarded as negligibly small. However, the number of KT recipients has increased recently. Furthermore, there are no reports about nationwide surveys on the prevalence and incidence of predialysis chronic kidney failure patients in Japan. This review describes our recent study on the estimated number of chronic kidney disease (CKD) stage G5 patients and the number of ESKD patients living in Japan, obtained via the cooperation of five related medical societies. From the results, as of Dec 31, 2007, 275,242 patients had received dialysis therapy and 10,013 patients had a functional transplanted kidney, and as of Dec 31, 2008, 286,406 patients had received dialysis therapy and 11,157 patients had a functional transplanted kidney. Consequently, there were 285,255 patients with CKD who reached ESKD and were living in Japan in 2008 and 297,563 in 2009. We also estimated that there were 67,000 predialysis CKD stage G5 patients in 2009, 37,365 patients introduced to dialysis therapy, and 101 patients who received pre-emptive renal transplantation in this year. In total, there were 37,466 patients who newly required renal replacement therapy (RRT) in 2009. Not only the average ages, but also the primary renal diseases of the new ESKD patients in each RRT modality were different.

摘要

终末期肾病(ESKD)的患病率和发病率在全球范围内持续上升。日本曾被认为是世界上 ESKD 患病率最高的国家;然而,这种情况在 2001 年被中国台湾所取代,美国仍位居第三。然而,日本和中国台湾的患病率数据仅包括接受透析治疗的患者。日本肾移植(KT)的患病率和发病率相当低,ESKD 患者中接受 KT 的人数被认为微不足道。然而,最近接受 KT 的人数有所增加。此外,日本没有关于全国范围内透析前慢性肾衰竭患者患病率和发病率的调查报道。本综述描述了我们最近的一项研究,该研究涉及通过五个相关医学协会合作估算的日本 G5 期慢性肾脏病(CKD)患者数量和接受透析治疗的 ESKD 患者数量。结果显示,截至 2007 年 12 月 31 日,已有 275242 名患者接受透析治疗,10013 名患者具有功能移植肾;截至 2008 年 12 月 31 日,286406 名患者接受透析治疗,11157 名患者具有功能移植肾。因此,2008 年和 2009 年在日本,CKD 患者中达到 ESKD 并存活的患者分别为 285255 人和 297563 人。我们还估计,2009 年有 67000 名透析前 CKD G5 期患者,其中 37365 名患者开始接受透析治疗,101 名患者在这一年接受了优先肾移植。2009 年共有 37466 名患者需要新的肾脏替代治疗(RRT)。不仅新 ESKD 患者的平均年龄,而且每种 RRT 方式的主要肾脏疾病都有所不同。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验